Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (OTCPK:HALB)

Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract

Accesswire April 4, 2024

Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing

Accesswire February 8, 2024

Halberd's Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on "The Street Reports Podcast"

Accesswire February 6, 2024

Halberd Corporation 2023 Year-End CEO Update and 2024 Goals

Accesswire January 11, 2024

CORRECTION BY SOURCE: Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX

Accesswire January 10, 2024

Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX

Accesswire January 9, 2024

Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com

Accesswire December 13, 2023

Halberd Corporation Plans to Extend Research Partnership with Mississippi State University

Accesswire November 15, 2023

Hartman, CEO, and Dr. Felder, CTO of Halberd Corp, Featured on The Street Reports Podcast

Accesswire October 10, 2023
View More News ››

Opinion & Analysis (OTCPK:HALB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (OTCPK:HALB)

Halberd's Patented Drug, LDN+, the Subject of a Limited ...

JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an...
AveragePenny - April 4, 2024

Halberd and Mississippi State University to Commence Stage

JACKSON CENTER, PA / ACCESSWIRE / February 8, 2024 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury...
averagepennies - February 8, 2024

Halberd's Top Executives Join Forces with Athena GTX CEO Mar

JACKSON CENTER, PA / ACCESSWIRE / February 6, 2024 / Halberd Corporation's (OTC PINK:HALB) and Athena GTX's executives...
averagepennies - February 6, 2024

Halberd Corporation 2023 Year-End CEO Update and 2024 Goals

2023 ACHIEVEMENTS Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on...
averagepennies - January 11, 2024

Halberd Corp. Signs Significant Revenue Sharing Agreement wi

Athena will employ its successful history of securing government contracts, spearheading such initiatives JACKSON CENTER, PA...
averagepennies - January 9, 2024

Halberd Corporation Signs Multi-Faceted Agreement with

Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal...
averagepennies - December 13, 2023
View more Bullboard ››

Fineqia International Inc.

Fineqia International Inc.

Fineqia is a digital asset business that builds and targets investments in early and growth-stage technology companies that ...
View More »